Welcome to our dedicated page for Fulcrum Therapeutics news (Ticker: FULC), a resource for investors and traders seeking the latest updates and insights on Fulcrum Therapeutics stock.
Fulcrum Therapeutics, Inc. (Nasdaq: FULC) is a clinical-stage biopharmaceutical company that reports frequent updates related to its work in genetically defined rare diseases. Company news regularly highlights progress for its lead program, pociredir, an investigational oral small molecule designed to increase fetal hemoglobin (HbF) for the treatment of sickle cell disease (SCD).
Investors and followers of FULC can expect news items covering clinical trial milestones, such as initial and updated data from the Phase 1b PIONEER trial of pociredir in adults with severe SCD. Fulcrum’s releases describe dose-escalation cohorts, changes in HbF levels, markers of hemolysis and anemia, and observations related to vaso-occlusive crises, along with safety and tolerability findings.
Fulcrum also issues corporate and financial announcements, including quarterly financial results, cash runway commentary, and details of public offerings of common stock and pre-funded warrants. Additional news may feature participation in major medical and investor conferences, such as the American Society of Hematology Annual Meeting and the J.P. Morgan Healthcare Conference, where the company presents clinical and preclinical data.
Other updates include disclosures on early-stage programs, such as calmodulin pathway modulators for bone marrow failure syndromes and preclinical data for EED inhibitor candidates in oncology models, as well as routine items like inducement stock option grants under Nasdaq Listing Rule 5635(c)(4). For readers tracking FULC, this news stream provides insight into the evolution of Fulcrum’s pipeline, its clinical development strategy in sickle cell disease, and its broader efforts in gene-expression modulation for rare diseases.
Fulcrum Therapeutics (Nasdaq: FULC) announced a successful closing of a $68.5 million private placement with institutional and accredited investors. The offering involved the sale of 4,029,411 shares at $17.00 per share. Proceeds will support research and development, focusing on losmapimod for facioscapulohumeral muscular dystrophy and potential COVID-19 applications, as well as advancing other clinical programs. The company will register the resale of shares with the SEC within 15 days. Forward-looking statements highlight potential operational risks.
Fulcrum Therapeutics (Nasdaq: FULC) has submitted an Investigational New Drug (IND) application to initiate a Phase 3 trial for losmapimod as a treatment for COVID-19. This decision follows prior clinical trials showing its potential to reduce inflammatory cytokines linked to poor COVID-19 prognosis. The company is also advancing its development programs for facioscapulohumeral dystrophy (FSHD) and sickle cell disease, with key milestones on track for late 2020. Fulcrum expects its financial resources to support operations into Q1 2022.
Fulcrum Therapeutics (Nasdaq: FULC) announced significant data presentations at the 2020 American Academy of Neurology's virtual platform, showcasing progress in developing losmapimod, a treatment for facioscapulohumeral muscular dystrophy (FSHD). The data includes a pharmacodynamic biomarker for treatment effect and a standardized MRI protocol for muscle evaluation. The company is conducting Phase 2 trials assessing losmapimod's efficacy in FSHD, a rare genetic disease affecting 16,000-38,000 patients in the U.S.
Fulcrum Therapeutics, Inc. (Nasdaq: FULC) will release its first quarter 2020 financial results on May 13, 2020, before the U.S. markets open. A conference call and webcast will follow at 8:00 a.m. ET, discussing these results and the latest corporate developments. The company is focused on treating genetically defined rare diseases, advancing its lead drug, losmapimod, to Phase 2 for facioscapulohumeral muscular dystrophy, while also working on FTX-6058 for sickle cell disease and beta-thalassemia.